computer based instrument validation - ipheb...
TRANSCRIPT
Page 1
Computer Based Instrument Validation
April 2012Brendan Somerville
Page 2
Content
Terms of Reference & OQ DriversFDA Warning Letters (OQ) Instrument Compliance ChoicesCompliance Trends & QuestionsAgilent ACE – Partner Edition
Page 3
FDA Focus on Data Integrity…..
• Differences Between ComputerRecords and Paper Print Outs
Difference
• High Profile Cases (e.g. Able Laboratories – Passed 11 PAI Inspections, but …. ) “Whistle Blower”
Page 4
Terms of Reference – FDA PAI
FOOD AND DRUG ADMINISTRATIONCOMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM 7346.832
Chapter 46 – New Drug ApplicationPRE-APPROVAL INSPECTIONS
3.3 INSPECTION / AUDIT STRATEGY
There are three primary inspectional objectives of this PAI program. These objectives are:
Objective 1: Readiness for Commercial ManufacturingObjective 2: Conformance to ApplicationObjective 3: Data Integrity Audit
• Data Integrity – is a core objective of FDA PAI !• FDA – is conducting Part 11 Audits during GMP Inspections• FDA – is being trained in Data Integrity by Monica Cahilly
Page 5
Compliance Drivers.....
• How do you keep up to date with compliance ?• Newsletters?• When Company Policy Changes ?• When You Are Told To ?• When “found out” in an Audit
• What is the “role” of the FDA ?• Historical Influence• Do You Supply to the USA ?• Mutual Recognition
• How do you know what is “good enough” ?
Page 7
Review of FDA Warning Letters - What OQ Problems do FDA Find ?
• OQ not good enough - Critical parts of system not qualified adequately
• People not adequately trained – FDA observe people doing the work
• No raw data for the work – Firm could not show inspectors the raw data
• Tools used were not calibrated – Tools used in an OQ must be calibrated
• OQ failures not detected – By person doing the work or managers checking it
• Data integrity – Data not secure and could have been tampered with
Google FDA Warning Letters….
Page 8
Review of FDA Warning Letters - What OQ Problems do FDA Find ?
Agilent ACE satisfies ALL requirements, including FDA warning letters.....
• OQ not good enough - Critical parts of system not qualified adequately
• People not adequately trained – FDA observe people doing the work
• No raw data for the work – Firm could not show inspectors the raw data
• Tools used were not calibrated – Tools used in an OQ must be calibrated
• OQ failures not detected – By person doing the work or managers checking it
• Data integrity – Data not secure and could have been tampered with
No Audit Problems / FDA 483 Warning Letters after > 150,000
Annual GMP Training / Retraining
Raw Data Electronically Added, No Customer Checking
Calibration Data Added to EQR
Management of Deviations is a CORE Feature of ACE
Scientific ACE Development – Guarantee Points & Limits
Facts:1.Agilent has never been cited in an FDA warning letter for qualification2.More warning letters are issued to “in house” OQ solutions !
Page 11
Don’t Do IT !
Do It Yourself (DIY)
Justify – what you don’t Do
Balance Control Vs RisksSpecialist / Supply ChainHidden Costs Not “Core” Lab. Business(May not be as “cheap” as it appears)
Justify – Alternative Interpretation
Customer – People Leaving......Risks – Training & Parts (Repair)
– Getting it WRONG !
Customer OQ and Compliance Choices......
Use the Original Equipment Manufacturer (OEM)
Possible Inflexible ApproachDifferent Qualification Strategy
Use Harmonised Approach All OQ’s are the same
Easier to DefendSimpler to Understand
Page 12
How Was The OQ Report Generated ?
Qualification Delivery
PaperManual process (cheap labour)Changeable, but not Flexible, Risk of errorManual processes - data integrity
Red
uced
Com
plia
nce
Ris
k
Page 13
FDA Direction on Paper Records
Industry Misinterpreted the 2003 Part 11 Scope & Applications Guidance !
“Printed chromatograms do not satisfy the predicate rules…..”
Page 14
Paper Protocols……
Are hard to do wellAre more prone to human errorsDifficult to include calculationsNeed checking……
Page 15
How Was The OQ Report Generated ?
Qualification Delivery
PaperManual process (cheap labour)Changeable, but not Flexible Risk of errorManual processes - data integrity
ExcelData TranscriptionVersion ControlValidation
Red
uced
Com
plia
nce
Ris
k
Page 16
Monica Cahilly – Training the FDA in Data Integrity
From Monica Cahilly, ISPE Conference – New Brunswick, USA – September 2011
Page 17
How Was The OQ Report Generated ?
Qualification Delivery
Paper
Hybrid
Manual process (cheap labour)Changeable, but not Flexible Risk of errorManual processes - data integrity
Potential Data integrity concerns ?FDA Publication 60052Manual Checking
ExcelData TranscriptionVersion ControlValidation
Red
uced
Com
plia
nce
Ris
k
Page 18
Many People Now Believe…….
From Monica Cahilly, ISPE Conference – New Brunswick, USA – September 2011
Page 19
How Was The OQ Report Generated ?
Qualification Delivery
Paper
Hybrid
Fully Electronic
Manual process (cheap labour)Changeable, but not Flexible Risk of errorManual processes - data integrity
Potential Data integrity concerns ?FDA Publication 60052Manual Checking
Remove Transcription ErrorsSecure Report GenerationMeta Data Preserves:“Content and Meaning”Electronic Data IndexingElectronic Storage
ExcelData TranscriptionVersion ControlValidation
Red
uced
Com
plia
nce
Ris
k
Page 20
Data Integrity – An Increasing Area of FDA Focus“There is a paradigm shift in the way FDA thinks about part 11”
Monica Cahilly, ISPE Conference on Risk-Based Systems ValidationNew Jersey, USA, 12-13th September 2011
Agilent ACE OQ satisfies the latest definitions required for data integrity:
FDA “ALCOA” requirements: Attributable
Legible
Original
Accurate
Contemporaneous
Complete
Consistent
Enduring
Available
“Engineer” Securely Logged OnDate / Time Stamps
Real Time Results Recording
Electronic Report
Secure PDF EQP Report
Secure Error Management / GMP
Monica is training FDA in Data Integrity
EQR is Full OQ Report
Full data transfer log
CDS, PDF, Print
On CD / Print....
Page 23
GAMP and USP <1058>
CommonGoals Good Issues
• Too Complex ?
• Software Focus
• Verify Vs Qualify
• Category 2 (gone)
• Over Simplified ?
• What AboutSoftware
• What AboutGroup C ……
• DQ “Ownership”
Trends
• IQ / OQ in USPGeneral Chapters
• PharmacopeiaForumStimulus Paper
• GAMP GPG(Validation of LaboratoryComputerized Systems)
• Risk Based( 7 Categories Gone !)
GAMP 5- 2008
AIQ <1058>- 2008
ISPE
USP
• Simplify Process
• Risk by Categorisation
• Roles andResponsibilities
• Maximise use of SupplierDocumentation
• 5 pages !
• Easy to Follow
• A and B Simple
• Flexible
• Better Than 4
• Very Comprehensive
• Great For CustomSoftware
GAMP 4- 2001
Page 25
Laboratory QualitySystem
HPLC (A)IQ / OQ
HPLC (B)IQ / OQ
Prep HPLCIQ / OQ
LC-MSIQ / OQ
Metals AnalysisIQ / OQ
Instrument Qualification Is An Integral Part of Your Quality System
• Different Definitions for IQ / OQ / PQ• Conflicting OQ / PQ Interpretation• Different Documentation:
- IQ / OQ / PQ Detail- Look & Feel
• Fixed Qualification - Relevance to your Application ?- Does it cover Your Range of Use ?
To Defend Lab. Results, Companies Must Defend the Instrument QualificationWell !
Where there is a Difference:Qualification Strategy and Rationale is Fragmented,
Time Consuming to Understand & Defend (Cost) + Risk....
Page 26
Explaining Your Instrument Qualification in an Audit……
ALL REGULATORY
inspectors can be Intimidating…….
Fragmented Qualification is Harder to Defend……
Page 27
Scientific Data Integrity ? - Prove the INTEGRITY of your Results
Did the Qualification Cover theRange of Use ?
Has the Qualification StatusBeen Maintained ?
• The Instrument was Qualified…. Etc.
• The Method Limits Was Validated
• The Correct Reference Materials Were Used
• Training Records - The Analyst Was Trained
• System Suitability – The Method Was Working Correctly
Can You Explain The QualificationRationale & Justify The Set Points & Limits ?
Prove that the data has not beentampered with….. ?
Page 29
How Many ? How Many Times are Techniques Cited ?
• KF – 2• FTIR – 3• FT-IR – 4• Infrared – 40• GC – 9• Dissolution – 35• UV – 36• HPLC – 51• Qualification – 247• Calibration – 336• Training – 895• Agilent - 0
• Pharmaceutical Manufacture• Medical Devices• Food Imports
• Neutraceuticals (Fundamental cGMP)
• Cosmetics• Tobacco Products
Page 30
2767 ?
FDA Warning Letters – Trends…..
www.fda.gov/downloads/ICECI/EnforcementActions
Num
ber o
f FD
A W
arni
ng L
ette
rs
Page 31
GAMP
USP <1058>
Part 11 / Annex 11
Data Integrity
GAMP 5 – Risk Based
GAMP Computer System Validation(7 Categories – Removed – Now Risk Based)
• FDA Surveillance Audits• Implementation (e.g. Network Qualification)
Risk BasedThinkingFlexibility
Mandatory Chapters - Qualification
Optional Chapters – Best Practice
Bob McDowallStimulus Paper- AAPS 2010
Monica CahillyISPE 12/13 September
Profound Implications for Compliance !
“In each case, we recommend that the copying process used produces copies that preserve the content and meaning of the record” [2003 Scope and Applications Guide]
Compliance Trends
Page 33
Evolution of Agilent Thinking….
Chromatography Data System (CDS)Or Instrument Software
• Instrument Control• Collect / Store Chromatograms• What YOU USE when you generate results
Qualification
CDS
Network
Instruments
(Annex 11)
Agilent ACE uses TNF (technology neutral format)
•Reads native file format or
•AIA output•Original and Meta Data Retained
(ACE)
Page 34
So, How Does ACE Work ?
ACE Runs from Spinning Hard Disc
ACE 2.1 is Client Server Enabled
• Engineer controls instrument in CDS• Engineer Sets ACE up For The Work• Engineer Uses ACE to browse for data • Compliance Data (file transfer details) Partner
Edition.....
Page 35
Enterprise Compliance Standardized Qualifications Across
Multi-vendor –Enterprise Compliance Delivery
2-wire analog detector output
NetworkInstrument
Control
Customer’s CDS
Empower
Enterprise EditionDelivery Model
Digital output
• Audit-ready paperless deliverables with electronic signatures
• Streamlined approval from equipment qualification plan to final report
• Robust vendor-neutral qualification platform
• Configurable testing conditions providing flexible delivery
• Chromatography Data System (CDS) agnostic
Global Solution providing Reproducible, Quality Deliverables with Full Traceability
Page 37
ACE 2.0 Overview Designed for Efficiency
Multiple sessions
Agilent Software Look
& FeelConfigurable
UI
Task instructions
Workflow based task
list
Attachment window
Work Type
Page 38
ACE ExampleWork Type
PM, IQ, OQRequalification,Software OQ
Select Technology- HPLC- GC - MS (GC-MS, LC-MS, (UPLC-MS)
- Dissolution- UV ….. Etc.
Ref. / Name
Configure(Software usedto Collect Data)
Page 41
ACE Computer Based Help – To Support Engineers & Partners
Partner Edition.....
Context Work Instructions
DetailedExplanations
Instrument Photographs
Page 42
Agilent Paperless Automated Compliance Engine
ACE efficiently enforces complianceWorkflow and rule based (simple to use, flexible to develop)
Enables electronic “execution” of Paper DocumentsReports free of transcription errorsElectronic chromatograms with meta dataPDF reports for efficient storage and reviewIntegrated GMP compliance:
Test execution counter (reports how many times a test was run)
Deviation justification and managementValidated calculationsAutomated Pass / Fail report.. Etc.
Page 43
Company Life Cycle - Compliance Maturity Curve
Time
Companies With High cGXP Expertise
Companies WithLower cGXPExpertise
Mature Pharmaceutical• Risk Management• Life Cycle Compliance• Aligned Compliance
Chemical Supplier, Start Up Company or ISO 9001• Avoidance Risk• Low Experience in Qualification • Need Qualification & Compliance Support
Agilent Compliance Solutions Support the Needs of these two differentapproaches
ACE
Partner Edition
Harmonised Approach
ACE
Standards / Limits + Compliance Delivery
Page 44
Summary
• Agilent is Closely Involved in Lab. Compliance
• Changes are Coming:• USP <1058> , GAMP, Data Integrity • Agilent is Closely Involved
• Move to Electronic and Away from Paper
• RISK Based Thinking NEEDSGreater Flexibility….. In Qualification
• ACE 2.0 + is Designed to Support These Needs
• Simple, Intuitive Interface
• Through our Partner program – we can train you !